Clinical Trial Update: A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating IPX056 for spasticity in subjects with multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Spasticity

Drugs mentioned

• IPX056

Snippet

Sponsor: Impax Laboratories, LLC | Conditions: Spasticity, Multiple Sclerosis | Phase 2 | Status: COMPLETED